General Medicine News and Research RSS Feed - General Medicine News and Research

Bayer expands patient assistance program for intrauterine devices

Bayer expands patient assistance program for intrauterine devices

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH (Access and Resources for Contraceptive Health) program will provide Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg and Mirena (levonorgestrel-releasing intrauterine system) 52 mg to low-income women who meet eligibility criteria. [More]
Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Takeda Pharmaceuticals International GmbH today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). [More]
New analysis takes comprehensive look at how patients feel about doctors' attire

New analysis takes comprehensive look at how patients feel about doctors' attire

What should doctors wear? And how does something as simple as their choice of a suit, scrubs or slacks influence how patients view them? [More]
Commonwealth Fund grant to support BIDMC's work on OurNotes

Commonwealth Fund grant to support BIDMC's work on OurNotes

Beth Israel Deaconess Medical Center has received a $450,000 grant from The Commonwealth Fund to develop OurNotes, an initiative to promote active patient engagement in health and illness that invites patients to contribute to their own electronic medical records. [More]
Improving headache treatment could reduce health care spending, new study suggests

Improving headache treatment could reduce health care spending, new study suggests

Each year more than 12 million Americans visit their doctors complaining of headaches, which result in lost productivity and costs of upward of $31 billion annually. A new study by researchers from Beth Israel Deaconess Medical Center suggests some of that cost could be offset by physicians ordering fewer tests and an increased focus on counseling about lifestyle changes. [More]
Tufts University researchers report that extra vitamin E can protect against pneumonia

Tufts University researchers report that extra vitamin E can protect against pneumonia

Extra vitamin E protected older mice from a bacterial infection that commonly causes pneumonia. Microbiologists and nutrition researchers from Tufts University report that the extra vitamin E helped regulate the mice's immune system. [More]
New study helps identify public health needs relating to HIV/AIDS, hepatitis C in Massachusetts

New study helps identify public health needs relating to HIV/AIDS, hepatitis C in Massachusetts

A new study from epidemiologists at Tufts University School of Medicine helps to identify communities with the greatest public health need in Massachusetts for resources relating to HIV/AIDS and hepatitis C. [More]
Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI). [More]
Suicidal ideation link to suicide strong in schizophrenia spectrum disorders

Suicidal ideation link to suicide strong in schizophrenia spectrum disorders

The association between suicidal ideation and later suicide is much stronger in patients with schizophrenia spectrum psychosis than in those with mood disorders, show results of a systematic meta-analysis. [More]
Study: Heart attack, stroke survivors' physical limitations rapidly increase over decade

Study: Heart attack, stroke survivors' physical limitations rapidly increase over decade

A record number of people are surviving heart attacks and stroke but those who do may experience a sharp decline in physical abilities that steadily accelerates over time, according to a new nationally-representative study led by the University of Michigan. [More]
Mortality gap persists for elderly men with severe mental disorders

Mortality gap persists for elderly men with severe mental disorders

The excess mortality experienced by men with severe mental disorders, compared with their mentally healthy peers, does not decrease with age, Australian research shows. [More]
Duke researchers develop new collaborative cancer care model for patients

Duke researchers develop new collaborative cancer care model for patients

Doctors at Duke University Hospital have developed a new collaborative model in cancer care that reduced the rates at which patients were sent to intensive care or readmitted to the hospital after discharge. [More]
BIDMC investigators develop three-minute assessment that identifies delirium in older hospital patients

BIDMC investigators develop three-minute assessment that identifies delirium in older hospital patients

Delirium is a state of confusion that develops suddenly, often following an acute medical illness, a surgical procedure or a hospitalization. Although delirium is estimated to complicate hospital stays for over 2.5 million elderly individuals in the U.S. each year, this common condition often goes undetected. The end result can be serious complications with sometimes devastating consequences for vulnerable hospitalized elders. [More]
FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures. [More]
Researchers explore effect of email exchanges between patients and physicians

Researchers explore effect of email exchanges between patients and physicians

Email has become one of the most widespread forms of communication, with its streamlined interactions benefiting both businesses and individuals. [More]
Retrospective study finds overuse of colonoscopies for colorectal cancer screening, surveillance

Retrospective study finds overuse of colonoscopies for colorectal cancer screening, surveillance

A retrospective study led by researchers at Brigham and Women's Hospital (BWH), has found an overuse of colonoscopies for colorectal cancer screening and surveillance. [More]
Viewpoints: Ezekiel Emanuel's choice of an age to die; new enrollment numbers still confusing

Viewpoints: Ezekiel Emanuel's choice of an age to die; new enrollment numbers still confusing

Seventy-five. That's how long I want to live: 75 years. This preference drives my daughters crazy. It drives my brothers crazy. My loving friends think I am crazy. They think that I can't mean what I say; that I haven't thought clearly about this, because there is so much in the world to see and do. To convince me of my errors, they enumerate the myriad people I know who are over 75 and doing quite well. They are certain that as I get closer to 75, I will push the desired age back to 80, then 85, maybe even 90. I am sure of my position. [More]
Cyclothymic temperament linked to suicidality

Cyclothymic temperament linked to suicidality

The presence of a cyclothymic temperament in inpatients with bipolar disorder may indicate a high likelihood of hopelessness and suicidality, report researchers. [More]
Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. [More]
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]